$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
帕博西尼单药最大的耐受剂量是多少?
2025-10-19 11:44:20
Check Details
乳腺癌服用拉帕替尼治疗之前需不需要进行HER-2基因检测
2025-10-19 11:44:20
Check Details
进展期胃癌服用拉帕替尼联合卡培他滨的疗效
2025-10-19 11:44:20
Check Details
来那替尼可否单独服用治疗HER2阳性乳腺癌?
2025-10-19 11:44:20
Check Details
乳腺癌服用达沙替尼和来曲唑联合治疗可获更长生存期
2025-10-19 11:44:20
Check Details
帕博西林有望治疗急性髓性白血病
2025-10-19 11:44:20
Check Details
美国食品药品管理局已批准奥拉帕尼用于治疗阳性卵巢癌
2025-10-19 11:44:20
Check Details
片剂型奥拉帕尼上市为患者带来了什么改变?
2025-10-19 11:44:20
Check Details
乳腺癌的治疗方案首选帕博西尼靶向药
2025-10-19 11:44:20
Check Details
来那替尼强化治疗乳腺癌的临床应用
2025-10-19 11:44:20
Check Details
HER2阳性乳腺癌服用来那替尼联合T-DM1可获得60%的生存期
2025-10-19 11:44:20
Check Details
奥拉帕尼的疗效比化疗的疗效高出两倍有余
2025-10-19 11:44:20
Check Details
1
2
...
1649
1650
1651
1652
1653
1654
1655
...
4158
4159
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
2
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights
3
Pemigatinib vs. Anlotinib: Key Differences Between FGFR-Targeted Therapy and Multi-Target Anti-Angiogenic Treatment
4
Lapatinib: A Targeted Anticancer Agent — Not Merely Symptom Relief
5
Lapatinib: Proper Administration Guide and Key Precautions
6
Capivasertib (Truqap) Complete Medication Guide: Indications, Dosing, Safety, and Precautions
7
Cemiplimab Storage and Handling Guide
8
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Dosing Duration, Efficacy Comparison, and Long-Term Management
9
Belzutifan (Welireg): Comprehensive Guide to the First HIF-2α Inhibitor — Indications, Dosing, and Safety Monitoring
10
Encorafenib (Braftovi): Comprehensive Guide to BRAF V600 Inhibitor Indications, Dose Regimens by Tumor Type, and Administration Requirements
11
Alpelisib vs Inavolisib: How to Choose Between Two PI3Kα Inhibitors in PIK3CA-Mutated Breast Cancer
12
Selumetinib: The First MEK1/2 Inhibitor Approved for Inoperable Plexiform Neurofibromas in NF1